FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

APPROVAL

ı	OMB Number:	3235-0287
ı	Estimated average burden	
ı	hours per response.	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	de pursuant to a or written plan for the equity securities of the ed to satisfy the conditions of Rule						
1. Name and Address Hippel James	of Reporting Person *		2. Issuer Name and Ticker or Trading Symbol BIO-TECHNE Corp [TECH]	5. Relat (Check	con(s) to Issuer		
(Last) 614 MCKINLEY	(First) PLACE NE	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 07/29/2025	X	Officer (give title below)	Other (specify below)	
(Street) MINNEAPOLIS MN 55413		55413	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indivi	Individual or Joint/Group Filing (Check Applic X Form filed by One Reporting Person Form filed by More than One Reporting		
(City)	(State)	(Zip)					

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transac Code (Ir 8)					Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(msu.4)
Common Stock	07/29/2025		M		168,620	A	\$44.33	275,230	D	
Common Stock	07/29/2025		F		147,431	D	\$58.55	127,799	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Stock Options (Right to Buy)	\$44.33	07/29/2025		М			168,620	(1)	08/08/2025	Common Stock	168,620	\$0	0	D	
Stock Options (Right to Buy)	\$47.6							(1)	08/07/2026	Common Stock	186,068		186,068	D	
Stock Options (Right to Buy)	\$66.97							(1)	08/05/2027	Common Stock	167,328		167,328	D	
Stock Options (Right to Buy)	\$120.46							(2)	08/06/2028	Common Stock	40,536		40,536	D	
Performance Restricted Stock Units	(3)							(4)	(4)	Common Stock	10,912		10,912	D	
Performance Stock Options (Right to Buy)	\$94.52							(4)	08/15/2029	Common Stock	33,916		33,916	D	
Stock Options (Right to Buy)	\$94.52							(5)	08/15/2029	Common Stock	45,220		45,220	D	
Performance Restricted Stock Units	(3)							(6)	(6)	Common Stock	13,865		13,865	D	
Performance Stock Options (Right to Buy)	\$84.61							(6)	08/15/2030	Common Stock	37,314		37,314	D	
Stock Options (Right to Buy)	\$84.61							(7)	08/15/2030	Common Stock	45,923		45,923	D	
Restricted Stock Units	(3)							(8)	(8)	Common Stock	13,159		13,159	D	
Performance Restricted Stock Units	(3)							(9)	(9)	Common Stock	24,062		24,062	D	
Restricted Stock Units	(3)							(10)	(10)	Common Stock	12,031		12,031	D	

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (In 8)		Derivative Expiration Date Securities (Month/Day/Year)		e and 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)			9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Stock Options (Right to Buy)	\$74.91							(11)	08/15/2034	Common Stock	32,417		32,417	D	
Restricted Stock Units	(3)							(12)	(12)	Common Stock	34,634		34,634	D	

Explanation of Responses:

- 1. Fully exercisable.
- 2. Options to purchase 10,134 shares vest on each of 8/6/2022, 8/6/2023, 8/6/2024 and 8/6/2025.
- 3. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock.
- 4. Vests in full or in part on 8/15/2025 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- $5.\ Options\ to\ purchase\ 11,305\ shares\ vest\ on\ each\ of\ 8/15/2023,\ 8/15/2024,\ 8/15/2025\ and\ 8/15/2026.$
- 6. Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- 7. Options to purchase 11,481 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027, and options to purchase 11,480 shares vest on 8/15/2026.
- 8. 13,159 restricted stock units vest on 11/1/2025.
- 9. Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- $10.\,4,\!010\ restricted\ stock\ units\ vest\ on\ each\ of\ 8/15/2025\ and\ 8/15/2026,\ and\ 4,\!011\ restricted\ stock\ units\ vest\ on\ 8/15/2027.$
- $11.\ Options\ to\ purchase\ 8,104\ shares\ vest\ on\ each\ of\ 8/15/2025,\ 8/15/2026\ and\ 8/15/2027,\ and\ options\ to\ purchase\ 8,105\ shares\ vest\ on\ 8/15/2028.$
- 12. 11,545 restricted stock units vest on each of 11/1/2025 and 11/1/2026; and 11,544 restricted stock units vest on 11/1/2027.

/s/ Andrew Nick as Attorney-in-Fact for James Hippel pursuant to 07/31/2025 Power of Attorney previously filed

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.